EBITDA of Recipharm 2008-2018

The EBITDA of the Swedish pharmaceutical company Recipharm generally increased, but with some fluctuations, during the period from 2008 to 2018. In 2018, EBITDA amounted to 56.5 million Swedish kronor, and in 2018, this amount had increased to 987.4 million Swedish kronor.

EBITDA of Recipharm from 2008 to 2018

EBITDA in million SEK
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

April 2019



Survey time period

2008 to 2018

Supplementary notes

Recipharm is a Swedish pharmaceutical contract development and manufacturing organization, founded in Stockholm in 1995.

Some figures are taken from previous publications.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.